Acetazolamide
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00819 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | exercise-induced malignant hyperthermia | KG + DL |
| 2 | hypertrophic cardiomyopathy | KG + DL |
| 3 | congenital myopathy with excess of thin filaments | KG + DL |
| 4 | hypertrophic cardiomyopathy due to intensive athletic training | KG + DL |
| 5 | distal myopathy, Tateyama type | KG + DL |
| 6 | cirrhotic cardiomyopathy | KG + DL |
| 7 | cardiomyopathy | KG + DL |
| 8 | intestinal obstruction | KG + DL |
| 9 | glycogen storage disease due to acid maltase deficiency, late-onset | KG + DL |
| 10 | myopathic intestinal pseudoobstruction | KG + DL |
| 11 | unclassified intestinal pseudoobstruction | KG + DL |
| 12 | familial hypertrophic cardiomyopathy | KG + DL |
| 13 | neuronal intestinal dysplasia, type B | KG + DL |
| 14 | familial isolated arrhythmogenic ventricular dysplasia | KG + DL |
| 15 | familial visceral myopathy | KG + DL |
| 16 | disorder of fatty acid oxidation and ketogenesis | KG + DL |
| 17 | glycogen storage disease due to glycogen branching enzyme deficiency | KG + DL |
| 18 | familial periodic paralysis | KG + DL |
| 19 | malignant hyperthermia, susceptibility to | KG + DL |
| 20 | hypokalemic periodic paralysis | KG + DL |
| 21 | endomyocardial fibrosis | KG + DL |
| 22 | carnitine-acylcarnitine translocase deficiency | KG + DL |
| 23 | trigeminal nerve neoplasm | KG + DL |
| 24 | moderate multiminicore disease with hand involvement | KG + DL |
| 25 | malignant hyperthermia of anesthesia | KG + DL |
| 26 | congenital multicore myopathy with external ophthalmoplegia | KG + DL |
| 27 | thyrotoxic periodic paralysis, susceptibility to | KG + DL |
| 28 | familial dilated cardiomyopathy | KG + DL |
| 29 | central core myopathy | KG + DL |
| 30 | mitochondrial DNA depletion syndrome 12a (cardiomyopathic type), autosomal dominant | KG + DL |
| 31 | thyrotoxic periodic paralysis | KG + DL |
| 32 | methemoglobinemia due to deficiency of methemoglobin reductase | KG + DL |
| 33 | King-Denborough syndrome | KG + DL |
| 34 | intestinal pseudoobstruction, neuronal, chronic idiopathic, X-linked | KG + DL |
| 35 | neuronal intestinal pseudoobstruction | KG + DL |
| 36 | methemoglobinemia, alpha type | KG + DL |
| 37 | dilated cardiomyopathy | KG + DL |
| 38 | gastroparesis (disease) | KG + DL |
| 39 | obsolete bundle branch block | KG + DL |
| 40 | aqueous misdirection | KG + DL |
| 41 | traumatic glaucoma | KG + DL |
| 42 | glaucomatous atrophy of optic disc | KG + DL |
| 43 | methemoglobin reductase deficiency | KG + DL |
| 44 | complex neurodevelopmental disorder | KG + DL |
| 45 | neovascular glaucoma | KG + DL |
| 46 | myopathy, centronuclear | KG + DL |
| 47 | pyruvate dehydrogenase E3 deficiency | KG + DL |
| 48 | idiopathic neonatal atrial flutter | KG + DL |
| 49 | methemoglobinemia | KG + DL |
| 50 | serotonin syndrome | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.